Aduro BioTech
Aduro Biotech | Engineered Immunotherapy for Cancer.
Launch date
Market cap
-
Enterprise valuation
$206—308m (Dealroom.co estimates Jan 2015.)
Berkeley California (HQ)
Financials
Estimates*
EUR | 2016 | 2017 | 2018 | 2019 |
---|---|---|---|---|
R&D budget | 35.0m | 60.0m | 46.0m | 38.0m |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
N/A | $3.9m | Series A | |
N/A | $1.8m | Convertible | |
N/A | $1.2m | Early VC | |
N/A | Series B | ||
N/A | N/A | Debt | |
N/A | N/A | Series B | |
N/A | N/A | Convertible | |
N/A | Series C | ||
$51.4m | Series D | ||
$25.0m | Post IPO Equity | ||
N/A | $119m | IPO | |
N/A | Merger | ||
* | N/A | $2.5m | Private Placement VC |
Total Funding | $60.8m |
Related Content
Recent News about Aduro BioTech
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Aduro BioTech
EditACQUISITION by Novartis Jun 2023